Versant’s new immunology biotech Santa Ana Bio snags Series A with GV, TPG partners on board

Prolific biotech investor Versant Ventures is brewing another startup, this time immunology player Santa Ana Bio, whose board includes partners from GV and TPG.

On its website, the California biotech says it has recently closed a Series A financing. An SEC filing from last month outlined plans for a $70...

Click to view original post